title: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
abstract: OBJECTIVE
  Febrile neutropenia remains a potentially life-threatening complication of anticancer chemotherapy, but some patients are at low risk for serious medical complications. The purpose of this study was to develop an internationally validated scoring system to identify these patients.
  
  
  METHODS
  Febrile neutropenic cancer patients were observed in a prospective multinational study. Independent factors assessable at fever onset, predicting low risk of complications, on a randomly selected derivation set, were assigned integer weights to develop a risk-index score, which was subsequently tested on a validation set.
  
  
  RESULTS
  On the derivation set (756 patients), predictive factors were a burden of illness indicating absence of symptoms or mild symptoms (weight, 5; odds ratio [OR], 8.21; 95% confidence interval [CI], 4.15 to 16.38) or moderate symptoms (weight, 3; OR, 3.70; 95% CI, 2.18 to 6.29); absence of hypotension (weight, 5; OR, 7.62; 95% CI, 2.91 to 19.89); absence of chronic obstructive pulmonary disease (weight, 4; OR, 5. 35; 95% CI, 1.86 to 15.46); presence of solid tumor or absence of previous fungal infection in patients with hematologic malignancies (weight, 4; OR, 5.07; 95% CI, 1.97 to 12.95); outpatient status (weight, 3; OR, 3.51; 95% CI, 2.02 to 6.04); absence of dehydration (weight, 3; OR, 3.81; 95% CI, 1.89 to 7.73); and age less than 60 years (weight, 2; OR, 2.45; 95% CI, 1.51 to 4.01). On the validation set, a Multinational Association for Supportive Care in Cancer risk-index score >/= 21 identified low-risk patients with a positive predictive value of 91%, specificity of 68%, and sensitivity of 71%.
  
  
  CONCLUSIONS
  The risk index accurately identifies patients at low risk for complications and may be used to select patients for testing therapeutic strategies that may be more convenient or cost-effective.
authors.affiliation: Institut Jules Bordet, Brussels, Belgium. jean.klastersky@bordet.be
authors.forename: J
authors.initials: J
authors.lastname: Klastersky
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: E B
authors.initials: EB
authors.lastname: Rubenstein
authors.forename: M
authors.initials: M
authors.lastname: Boyer
authors.forename: L
authors.initials: L
authors.lastname: Elting
authors.forename: R
authors.initials: R
authors.lastname: Feld
authors.forename: J
authors.initials: J
authors.lastname: Gallagher
authors.forename: J
authors.initials: J
authors.lastname: Herrstedt
authors.forename: B
authors.initials: B
authors.lastname: Rapoport
authors.forename: K
authors.initials: K
authors.lastname: Rolston
authors.forename: J
authors.initials: J
authors.lastname: Talcott
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D017063:Outcome Assessment, Health Care; D018579:Patient Selection; D011379:Prognosis; D011446:Prospective Studies; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents